

LAW OFFICES
FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P.
1300 I Street, N.W.
Washington, DC 20005-3315

Telephone
(202) 408-4000

Facsimile
(202) 408-4400

FACSIMILE TRANSMITTAL

Name: Ms. Nancy Johnson

Name: Steven J. Scott

Firm: U.S. Patent and Trademark Office
Office of Petitions

Phone No.: (202) 408-4231

Fax No.: (703) 308 6916

Fax # Verified by:
Date: August 7, 2003

FAX RECEIVED

Phone No.: (703) 305 0309

Pages (incl. this): 12

AUG 07 2003

Subject: Application No. 09/662,649

Confirmation - No

PETITIONS OFFICE

Dear Ms. Johnson:

Thank you for speaking with me a few days ago. I enclose a Petition to have a recent assignee named on the patent that will issue from this application. The Petition includes copies of the papers we filed today with the Assignment Recordation Services. The Petition also authorizes the Petition fee to be charged to our deposit account.

Please contact me if you would like any further information.

Certificate of Transmission:

I hereby certify that this correspondence is being facsimile transmitted to the Patent and Trademark Office on August 7, 2003.

Signature



Steven J. Scott
Reg. No. 43,911

If there is a problem with this transmission, notify fax room at (202) 408-4174 or the sender at the number above.

This facsimile is intended only for the individual to whom it is addressed and may contain information that is privileged, confidential, or exempt from disclosure under applicable law. If you have received this facsimile in error, please notify the sender immediately by telephone (collect), and return the original message by first-class mail to the above address.

PATENT
Customer No. 22,852
Attorney Docket No. 02481.1690

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Zaid JAYYOSI et al.) Group Art Unit: 1624
Application No.: 09/662,649) Examiner: S. Patel
Filed: September 14, 2000) ATTN: Office of Petitions

For: THERAPEUTIC USES OF DI-ARYL ACID DERIVATIVES

**Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450**

Sir.

FAX RECEIVED
AUG 07 2003
PETITIONS OFFICE

Petition under 37 C.F.R. § 1.183

Applicants submit this Petition under 37 C.F.R. § 1.183 to waive the requirements of 37 C.F.R. § 3.81(a) and to permit the correct name of the assignee to be printed on the patent that issues from this application.

This application was allowed on May 1, 2003, and applicants paid the issue fee on July 31, 2003. The Issue Fee Transmittal Form PTOL-85B submitted by the applicants named "Aventis Pharmaceuticals Products Inc." as the assignee of the application. It is applicants' understanding that 37 C.F.R. § 3.81(a) allows the patent issuing from this application to issue in the name of that assignee.

On August 6, 2003, this application was assigned to "Aventis Pharma Deutschland GmbH." On August 7, 2003, applicants submitted the Assignment to the Assignment Recordation Services of the U.S. Patent and Trademark Office with a direction to record the Assignment pursuant to 37 C.F.R. § 3.28. Applicants enclose copies of those documents with this Petition.

In view of the recent Assignment discussed above, applicants hereby petition to waive the requirements of 37 C.F.R. § 3.81(a) and to have the patent issue from this application in the name of the current assignee "Aventis Pharma Deutschland GmbH."

**Application No. 09/662,649
Attorney Docket No. 02481.1690**

A fee of \$130.00 required by 37 C.F.R. § 1.17(h) is due for this Petition.
Applicants respectfully request that the Office charge this fee, as well as any required
excess or any other required fees, to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

By: 

Steven J. Scott
Reg. No. 43,911

Date: August 7, 2003

PATENT
Customer No. 22,852
Attorney Docket No. 02481.1690

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Zald JAYYOSI et al.) Group Art Unit: 1624
Application No.: 09/662,649) Examiner: S. Patel
Filed: September 14, 2000)

For: **THERAPEUTIC USES OF DI-ARYL ACID DERIVATIVES**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

FAX RECEIVED
AUG 07 2003
PETITIONS RECEIVED

Submission of Assignments

Applicants enclose two assignment documents for recordation in this application. The first assignment, attached in Exhibit A, effects a change of name and address from the presently-recorded assignee "Aventis Pharmaceuticals Products Inc." to "Aventis Pharmaceuticals Inc."

The second assignment, attached as Exhibit B, effects an Assignment from "Aventis Pharmaceuticals Inc." to "Aventis Pharma Deutschland GmbH." Applicants include separate Recordation Form Cover Sheets for each assignment. Two checks in the amount of \$40.00 are also enclosed for the two recordation fees.

Applicants respectfully request that the Office record the two attached assignments and charge any other required fees to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

By: Steven J. Scott
Steven J. Scott
Reg. No. 43,911

Date: August 7, 2003

Exhibit A

FORM PTO-1595
1-31-92RECORDATION FORM COVER SHEET
PATENTS ONLYU.S. Department of Commerce
Patent and Trademark Office
Attorney Docket No. 02481.1690
Attorney Customer Number: 22,852To the Director of the U.S. Patent and Trademark Office:
Please record the attached original documents or copy thereof.

Mail Stop Assignment Recordation Services

1. Name of conveying party(ies):
Aventis Pharmaceuticals Products Inc.2. Name and address of receiving party(ies):
Name: Aventis Pharmaceuticals Inc.Additional name(s) of conveying party(ies) attached? Yes No

Internal Address:

3. Nature of conveyance: Street Address: 300 Somerset Corporate Boulevard

<input type="checkbox"/> Assignment	<input type="checkbox"/> Merger	City: Bridgewater		
<input type="checkbox"/> Security Agreement	<input checked="" type="checkbox"/> Change of Name	State: NJ	Zip Code: 08807	
<input type="checkbox"/> Other:		Additional name(s) & Address(es) attached?		

Execution Date: December 31, 2001

 Yes No

4. Application number(s) or patent number(s): If this document is being filed together with a new application, the execution date of the application:

A. Patent Application Number(s):

09/662,849

B. Patent Number(s):

Additional numbers attached? Yes No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Steven J. Scott

6. Total number of applications and registrations involved:
One (1)

7. Total fee (37 CFR 3.41): \$40

Enclosed (Please charge deficiency to deposit account)
 Authorized to be charged to deposit account

Internal Address: FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P.

Street Address: 1300 I Street, N.W.


City: Washington, D.C.

State: Zip: 20005-3315

8. Deposit Account No.: 06-0916

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.



August 7, 2003

Steven J. Scott, Reg. No. 43,911

Signature

Date

Total number of pages including cover sheet, attachments and documents: Three (3)

Delaware

PAGE 1

The First State

I, HARRIET SMITH WINDSOR, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF AMENDMENT OF "AVENTIS PHARMACEUTICALS PRODUCTS INC.", CHANGING ITS NAME FROM "AVENTIS PHARMACEUTICALS PRODUCTS INC." TO "AVENTIS PHARMACEUTICALS INC.", FILED IN THIS OFFICE ON THE THIRTY-FIRST DAY OF DECEMBER, A.D. 2001, AT 10:50 O'CLOCK P.M.

0631221 8100



Harriet Smith Windsor
Harriet Smith Windsor, Secretary of State

AUTHENTICATION: 1571269

TOTAL P.08

STATE OF DELAWARE
SECRETARY OF STATE
DIVISION OF CORPORATIONS
FILED 10:50 PM 12/31/2001
020028952 - 0631223

**CERTIFICATE OF AMENDMENT TO THE
CERTIFICATE OF INCORPORATION
OF
AVENTIS PHARMACEUTICALS PRODUCTS INC.**

The undersigned, Edward H. Stratemeyer, Vice President and Owen K. Ball, Jr., Assistant Secretary of Aventis Pharmaceuticals Products Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the "Corporation"), on behalf of the Corporation, hereby certify as follows:

FIRST: That the Board of Directors of the Corporation, by the unanimous written consent of its members, as filed with the minutes of the Board of Directors, adopted a resolution proposing and declaring advisable the following amendment to the Certificate of Incorporation amending the First Article thereof so that, as amended, said Article shall be and read as follows:

"FIRST: The name of the corporation is:

AVENTIS PHARMACEUTICALS INC."

SECOND: That in lieu of a meeting and vote of stockholders, the stockholders have given unanimous written consent to said amendment in accordance with the provisions of Section 228 of the General Corporation Law of the State of Delaware.

THIRD: That the aforesaid amendment was duly adopted in accordance with the applicable provisions of Sections 242 and 228 of the General Corporation Law of the State of Delaware.

FOURTH: The effective date of this amendment is December 31, 2001 at 10:30 pm.

IN WITNESS WHEREOF, we, Edward H. Stratemeyer, Vice President and Owen K. Ball, Jr., Asst. Secretary of Aventis Pharmaceuticals Products Inc., have signed this Certificate under the corporate seal of the Corporation on the 31st day of December 2001.

Aventis Pharmaceuticals Products Inc.


Edward H. Stratemeyer, Vice President



Owen K. Ball, Jr. Asst. Secretary

Exhibit B

FORM PTO-1595
1-31-92RECORDATION FORM COVER SHEET
PATENTS ONLYU.S. Department of Commerce
Patent and Trademark Office
Attorney Docket No. 02481.1690
Attorney Customer Number: 22,852To the Director of the U.S. Patent and Trademark Office:
Please record the attached original documents or copy thereof.

Mail Stop Assignment Recordation Services

1. Name of conveying party(ies):
Aventis Pharmaceuticals Inc.2. Name and address of receiving party(ies):
Name: Aventis Pharma Deutschland GmbHAdditional name(s) of conveying party(ies) attached? Yes No

Internal Address: 65926 Frankfurt am Main, Germany

3. Nature of conveyance: Street Address:

<input checked="" type="checkbox"/> Assignment	<input type="checkbox"/> Merger	City:		
<input type="checkbox"/> Security Agreement	<input type="checkbox"/> Change of Name	State:		Zip Code:
<input type="checkbox"/> Other:				

Additional name(s) & Address(es) attached?

Execution Date: August 6, 2003

 Yes No

4. Application number(s) or patent number(s): If this document is being filed together with a new application, the execution date of the application:

A. Patent Application Number(s):

09/662,649

B. Patent Number(s):

Additional numbers attached?

 Yes No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Steven J. Scott

6. Total number of applications and registrations involved:
One (1)

7. Total fee (37 CFR 3.41): \$40

Enclosed (Please charge deficiency to deposit account)

Authorized to be charged to deposit account

Internal Address: FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P.

Street Address: 1300 I Street, N.W.

City: Washington, D.C.

State: Zip: 20005-3315

B. Deposit Account No.: 06-0916

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Steven J. Scott, Reg. No. 43,911

Signature

August 7, 2003

Date

Total number of pages including cover sheet, attachments and documents: Three (3)

Application No. 09/662,649
Attorney Docket No. 02481.1690

ASSIGNMENT

WHEREAS Aventis Pharmaceuticals Inc., a corporation having an address at 300 Somerset Corporate Boulevard, Bridgewater, New Jersey 08807-2854 [hereinafter referred to as "AVENTIS PHARMACEUTICALS"], is assignee of the entire right, title, and interest in and to the invention disclosed and claimed in U.S. application no. 09/662,649, filed on September 14, 2000;

and

WHEREAS, Aventis Pharma Deutschland GmbH, a corporation of Germany, [hereinafter referred to as "AVENTIS PHARMA DEUTSCHLAND"] whose address is 65926 Frankfurt am Main, Germany, is desirous of securing the entire right, title, and interest in and to this invention, the application for United States Letters Patent on this invention and the Letters Patent to be issued upon this application;

NOW THEREFORE, be it known that, for good and valuable consideration the receipt of which from AVENTIS PHARMA DEUTSCHLAND is hereby acknowledged, AVENTIS PHARMACEUTICALS has sold, assigned, transferred, and set over, and does hereby sell, assign, transfer, and set over unto AVENTIS PHARMA DEUTSCHLAND, its lawful successors and assigns, its entire right, title, and interest in and to this invention and this application, and all divisions, and continuations thereof, and all Letters Patent of the United States which may be granted thereon, and all reissues thereof; and AVENTIS PHARMACEUTICALS hereby authorizes and requests the Commissioner of Patents and Trademarks of the United States to issue all Letters Patent for this invention to AVENTIS PHARMA DEUTSCHLAND, its successors and assigns, in accordance with the terms of this Assignment;

AND, AVENTIS PHARMACEUTICALS HEREBY further covenants and agrees that it will, without further consideration, communicate with AVENTIS PHARMA DEUTSCHLAND, its successors and assigns, any facts known to it respecting this invention and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver all papers that may be necessary or desirable to perfect the title to this invention in AVENTIS PHARMA DEUTSCHLAND, its successors and assigns, execute all divisional, continuation, and reissue applications, make all rightful oaths and generally do everything possible to aid AVENTIS PHARMA DEUTSCHLAND, its successors and assigns, to obtain and enforce proper patent protection for this invention in the United States, it being understood that any expense incident to the execution of such papers shall be borne by AVENTIS PHARMA DEUTSCHLAND, its successors and assigns.

Application No. 09/562,649
Attorney Docket No. 02481.1690

The undersigned, whose title is supplied below, is empowered to sign this
Assignment on behalf of AVENTIS PHARMACEUTICALS.

County of SOMERSET) Name: Aventis Pharmaceuticals Inc.
) ss. Address: 300 Somerset Corporate Boulevard
)) Bridgewater, New Jersey 08807-2854
State of NEW JERSEY) By: RJ Oehler
) Title: ROSS J. OEHLER
) Date: 8/6/03 ASSISTANT SECRETARY

Subscribed and sworn to before me this 6th day of August, 2003

ROSS J. OEHLER, Notary Public
BAYA REINHOLD
NOTARY PUBLIC OF NEW JERSEY
MY COMMISSION EXPIRES MAR. 14, 2007